A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Trial Profile

A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Olipudase alfa (Primary)
  • Indications Niemann-Pick diseases
  • Focus Therapeutic Use
  • Acronyms ASCEND
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 15 Jun 2017 This trial has been suspended in Portugal.
    • 15 Jun 2017 This trial has been suspended in Portugal.
    • 22 Feb 2017 Planned End Date changed from 1 Oct 2022 to 1 Jul 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top